Investigation of bioactivation of ticlopidine using linear ion trap/orbitrap mass spectrometry and an improved mass defect filtering technique

Chemical Research in Toxicology

Volumn 23, Issue 5, 2010, Pages 909-917

  Ruan, Qian ^a   Zhu, Mingshe ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; GLUTATHIONE; TICLOPIDINE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; EPOXIDATION; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; NONHUMAN; OXIDATION; RAT;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; GLUTATHIONE; HUMANS; MICROSOMES, LIVER; PLATELET AGGREGATION INHIBITORS; RATS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TICLOPIDINE;

RATTUS;

EID: 77952400154     PISSN: 0893228X     EISSN: 15205010     Source Type: Journal    
DOI: 10.1021/tx1000046     Document Type: Article

References (46)

1. Di Minno, G., Cerbone, A. M., Mattioli, P. L., Turco, S., Iovine, C., and Mancini, M. (1985) Functionally thrombasthenic state in normal platelets following the administration of ticlopidine J. Clin. Invest. 75, 328-338
2. Colli, A., Buccino, G., Cocciolo, M., Parravicini, R., Elli, G. M., and Scaltrini, G. (1987) Ticlopidine-theophylline interaction Clin. Pharmacol. Ther. 41, 358-362
3. McTavish, D., Faulds, D., and Goa, K. L. (1990) Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders Drugs 40, 238-259
4. Hass, W. K., Easton, J. D., Adams, H. P., Jr., Pryse-Phillips, W., Molony, B. A., Anderson, S., and Kamm, B. (1989) A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group N. Engl. J. Med. 321, 501-507 (Pubitemid 19203874)
5. Flores-Runk, P. and Raasch, R. H. (1993) Ticlopidine and antiplatelet therapy Ann. Pharmacother. 27, 1090-1098
6. Hsi, D. H., Mock, D. J., and Rocco, T. A., Jr. (1999) Toxic erythroderma due to ticlopidine N. Engl. J. Med. 340, 1212
7. Whetsel, T. R. and Bell, D. M. (1999) Rash in patients receiving ticlopidine after intracoronary stent placement Pharmacotherapy 19, 228-231
8. Swine, C., Cornette, P., Van Pee, D., Delos, M., and Melange, M. (1998) Ticlopidine, diarrhea and lymphocytic colitis Gastroenterol. Clin. Biol. 22, 475-476
9. Gent, M., Blakely, J. A., Easton, J. D., Ellis, D. J., Hachinski, V. C., Harbison, J. W., Panak, E., Roberts, R. S., Sicurella, J., and Turpie, A. G. (1989) The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke Lancet 1, 1215-1220 (Pubitemid 19140324)
10. De Gramont, A., Canuel, C., Krulik, M., Bauters, F., Degos, L., Marty, M., and Najean, Y. (1982) Hematological toxicity of ticlopidine Nouv. Rev. Fr. Hematol. 24, 35-37
11. Love, B. B., Biller, J., and Gent, M. (1998) Adverse haematological effects of ticlopidine. Prevention, recognition and management Drug Saf. 19, 89-98
12. Ono, K., Kurohara, K., Yoshihara, M., Shimamoto, Y., and Yamaguchi, M. (1991) Agranulocytosis caused by ticlopidine and its mechanism Am. J. Hematol. 37, 239-242
13. Chen, L. K., Hsieh, B. H., Chen, W. C., Tsai, S. T., and Hou, M. C. (2001) Ticlopidine-induced hepatitis Zhonghua Yi Xue Za Zhi (Taipei) 64, 59-63
14. Pizarro, A. E., Andrade, R. J., Garcia-Cortes, M., Lucena, M. I., Perez-Moreno, J. M., Puertas, M., Sanchez-Martinez, H., Montero, J. L., Duran, J. A., Jimenez, M., Ruiz-Montero, A., Soto-Conesa, M. J., Rodrigo, L., de Francisco, R., Alcantara, R., and Camargo, R. (2001) Acute hepatitis due to ticlopidine. A report of 12 cases and review of the literature Rev. Neurol. 33, 1014-1020
15. Lucena, M. I., Camargo, R., Andrade, R. J., Perez-Sanchez, C. J., and Sanchez De La Cuesta, F. (2001) Comparison of two clinical scales for causality assessment in hepatotoxicity Hepatology 33, 123-130
16. Skurnik, Y. D., Tcherniak, A., Edlan, K., and Sthoeger, Z. (2003) Ticlopidine-induced cholestatic hepatitis Ann. Pharmacother. 37, 371-375
17. Mizushima, M., Iwata, N., Fujimoto, T. T., Ishikawa, K., and Fujimura, K. (2005) Patient characteristics in ticlopidine hydrochloride-induced liver injury: Case-control study Hepatol. Res. 33, 234-240
18. Valadon, P., Dansette, P. M., Girault, J. P., Amar, C., and Mansuy, D. (1996) Thiophene sulfoxides as reactive metabolites: Formation upon microsomal oxidation of a 3-aroylthiophene and fate in the presence of nucleophiles in vitro and in vivo Chem. Res. Toxicol. 9, 1403-1413
19. Liu, Z. C. and Uetrecht, J. P. (2000) Metabolism of ticlopidine by activated neutrophils: Implications for ticlopidine-induced agranulocytosis Drug Metab. Dispos. 28, 726-730
20. Kraslova, I., Muchova, L., Vitek, L., Novotny, A., Svestka, T., and Bruha, R. (2006) Ticlopidine-induced cholestatic inflammatory hepatitis: new insight into pathogenetic mechanisms of drug-related hepatoxicity Eur. J. Inflammation 4, 55-67
21. Takakusa, H., Masumoto, H., Mitsuru, A., Okazaki, O., and Sudo, K. (2008) Markers of electrophilic stress caused by chemically reactive metabolites in human hepatocytes Drug Metab. Dispos. 36, 816-823
22. Tuong, A., Bouyssou, A., Paret, J., and Cuong, T. G. (1981) Metabolism of triclopidine in rats: Identification and quantitative determination of some its metabolites in plasma, urine and bile Eur. J. Drug Metab. Pharmacokinet. 6, 91-98
23. Desager, J. P. (1994) Clinical pharmacokinetics of ticlopidine Clin. Pharmacokinet. 26, 347-355
24. Dansette, P. M., Bertho, G., and Mansuy, D. (2005) First evidence that cytochrome P450 may catalyze both S-oxidation and epoxidation of thiophene derivatives Biochem. Biophys. Res. Commun. 338, 450-455
25. Ha-Duong, N. T., Dijols, S., Macherey, A. C., Goldstein, J. A., Dansette, P. M., and Mansuy, D. (2001) Ticlopidine as a selective mechanism-based inhibitor of human cytochrome P450 2C19 Biochemistry (Moscow) 40, 12112-12122
26. Shimizu, S., Atsumi, R., Nakazawa, T., Fujimaki, Y., Sudo, K., and Okazaki, O. (2009) Metabolism of ticlopidine in rats: Identification of the main biliary metabolite as a glutathione conjugate of ticlopidine S-oxide Drug Metab. Dispos. 37, 1904-1915
27. Wen, B., Ma, L., Nelson, S. D., and Zhu, M. (2008) High-throughput screening and characterization of reactive metabolites using polarity switching of hybrid triple quadrupole linear ion trap mass spectrometry Anal. Chem. 80, 1788-1799
28. Rousu, T., Pelkonen, O., and Tolonen, A. (2009) Rapid detection and characterization of reactive drug metabolites in vitro using several isotope-labeled trapping agents and ultra-performance liquid chromatography/time-of-flight mass spectrometry Rapid Commun. Mass Spectrom. 23, 843-855
29. Lim, H. K., Chen, J., Cook, K., Sensenhauser, C., Silva, J., and Evans, D. C. (2008) A generic method to detect electrophilic intermediates using isotopic pattern triggered data-dependent high-resolution accurate mass spectrometry Rapid Commun. Mass Spectrom. 22, 1295-1311
30. Zhang, H., Zhang, D., and Ray, K. (2003) A software filter to remove interference ions from drug metabolites in accurate mass liquid chromatography/mass spectrometric analyses J. Mass Spectrom. 38, 1110-1112
31. Zhu, M., Ma, L., Zhang, H., and Humphreys, W. G. (2007) Detection and structural characterization of glutathione-trapped reactive metabolites using liquid chromatography-high-resolution mass spectrometry and mass defect filtering Anal. Chem. 79, 8333-8341
32. Zhang, H., Zhu, M., Ray, K. L., Ma, L., and Zhang, D. (2008) Mass defect profiles of biological matrices and the general applicability of mass defect filtering for metabolite detection Rapid Commun. Mass Spectrom. 22, 2082-2088
33. Zhang, H., Zhang, D., Ray, K., and Zhu, M. (2009) Mass defect filter technique and its applications to drug metabolite identification by high-resolution mass spectrometry J. Mass Spectrom. 44, 999-1016
34. Zhang, H., Ma, L., He, K., and Zhu, M. (2008) An algorithm for thorough background subtraction from high-resolution LC/MS data: application to the detection of troglitazone metabolites in rat plasma, bile, and urine J. Mass Spectrom. 43, 1191-1200
35. Zhu, M., Ma, L., Zhang, D., Ray, K., Zhao, W., Humphreys, W. G., Skiles, G., Sanders, M., and Zhang, H. (2006) Detection and characterization of metabolites in biological matrices using mass defect filtering of liquid chromatography/high resolution mass spectrometry data Drug Metab. Dispos. 34, 1722-1733
36. ODonnell, J. P., Dalvie, D. K., Kalgutkar, A. S., and Obach, R. S. (2003) Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen Drug Metab. Dispos. 31, 1369-1377
37. Graham, E. E., Walsh, R. J., Hirst, C. M., Maggs, J. L., Martin, S., Wild, M. J., Wilson, I. D., Harding, J. R., Kenna, J. G., Peter, R. M., Williams, D. P., and Park, B. K. (2008) Identification of the thiophene ring of methapyrilene as a novel bioactivation-dependent hepatic toxicophore J. Pharmacol. Exp. Ther. 326, 657-671
38. Dansette, P. M., Libraire, J., Bertho, G., and Mansuy, D. (2009) Metabolic oxidative cleavage of thioesters: Evidence for the formation of sulfenic acid intermediates in the bioactivation of the antithrombotic prodrugs ticlopidine and clopidogrel Chem. Res. Toxicol. 22, 369-373
39. Takakusa, H., Masumoto, H., Makino, C., Okazaki, O., and Sudo, K. (2009) Quantitative assessment of reactive metabolite formation using 35S-labeled glutathione Drug Metab. Pharmacokinet. 24, 100-107
40. Hirata, K., Takagi, H., Yamamoto, M., Matsumoto, T., Nishiya, T., Mori, K., Shimizu, S., Masumoto, H., and Okutani, Y. (2008) Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: A preliminary case-control study Pharmacogenomics J. 8, 29-33
41. Dalvie, D. K. and OConnell, T. N. (2004) Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes p450, and monoamine oxidases Drug Metab. Dispos. 32, 49-57
42. Castagnoli, N., Jr., Rimoldi, J. M., Bloomquist, J., and Castagnoli, K. P. (1997) Potential metabolic bioactivation pathways involving cyclic tertiary amines and azaarenes Chem. Res. Toxicol. 10, 924-940
43. Bruno, J. J. and Molony, B. A. (1983) Ticlopidine Cardiovasc. Drug Rev. 1, 295-316
44. Guengerich, F. P. (2006) Cytochrome P450s and other enzymes in drug metabolism and toxicity AAPS J. 8, E101-E111
45. Holt, M. P. and Ju, C. (2006) Mechanisms of drug-induced liver injury AAPS J. 8, E48-E54
46. Park, K. B., Dalton-Brown, E., Hirst, C., and Williams, D. P. (2006) Selection of new chemical entities with decreased potential for adverse drug reactions Eur. J. Pharmacol. 549, 1-8